Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Whole blood transfusion Clear all
Not yet recruiting Not applicable Interventional

Hypoxic Red Blood Cells in Sickle Cell Anemia

NCT06743113
View directory record Official record
Conditions
Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions
Hemanext ONE System, Conventional RBCs
Device
Lead sponsor
Hemanext
Industry
Eligibility
7 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
5
States / cities
Farmington, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 5:24 AM EDT
Recruiting Phase 3 Interventional

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

NCT06070350
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma Injury
Interventions
Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
Biological · Drug
Lead sponsor
Philip Spinella
Other
Eligibility
Up to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 11, 2026, 5:24 AM EDT
Recruiting Early Phase 1 Interventional

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

NCT03849443
View directory record Official record
Conditions
Open Posterior Thoracolumbar Spinal Fusion Procedure
Interventions
Tranexamic Acid Injectable Product (1000 mg intravenous bolus), Vitamin C 250 MG Oral Tablet, Tranexamic Acid 650Mg Tablet
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications

NCT02094118
View directory record Official record
Conditions
Blood Transfusion Complications
Interventions
Point-of-care washed red blood cell transfusion., Standard of care red blood cell transfusion.
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 11, 2026, 5:24 AM EDT
Not listed Phase 1Phase 2 Interventional

Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

NCT00319657
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 11, 2026, 5:24 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants

NCT06045689
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Los Alamitos, California • New Haven, Connecticut • St. Petersburg, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 11, 2026, 5:24 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion

NCT01949896
View directory record Official record
Conditions
Transfusions
Interventions
NPO, Control group: continue feedings
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
3 Days to 6 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

NCT04269707
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Miami Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Not applicable Interventional

Restrictive Versus Liberal Transfusion Protocol in Infants Undergoing Cardiac Surgery

NCT01484886
View directory record Official record
Conditions
Impaired Oxygen Delivery, Congenital Heart Disease
Interventions
Red blood cell transfusion
Other
Lead sponsor
University of Rochester
Other
Eligibility
Up to 7 Months
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

NCT02253654
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Anemia, Renal Dialysis, Erythrocyte Transfusion
Interventions
Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Cerritos, California • Glendale, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 11, 2026, 5:24 AM EDT
Not listed Not applicable Interventional

PREMOD2 With Near Infrared Spectroscopy Sub-study

NCT03145142
View directory record Official record
Conditions
Hypoxia, Brain, Premature Birth
Interventions
Umbilical cord milking, Delayed Cord Clamping
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 28 Weeks
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

Low-Titer O Positive Whole Blood Versus Component Therapy for Emergent Transfusion in Trauma Patients

NCT05081063
View directory record Official record
Conditions
Hemorrhagic Shock, Acute Blood Loss Anemia, Traumatic Brain Injury
Interventions
Routine labs
Combination Product
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older · Male only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 2 Interventional Results available

FM 140 vs FM100 Study in Patients With Multiple Myeloma

NCT00505895
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Fludarabine, Stem Cell Infusion, Rituximab
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 3 Interventional

A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy

NCT02145871
View directory record Official record
Conditions
Bladder Cancer
Interventions
standard fluid management, fluid management guided by the EV1000
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 11, 2026, 5:24 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Feasibility Study of Mirasol-Treated Whole Blood Red Cell Recovery and Survival

NCT00742001
View directory record Official record
Conditions
Healthy
Interventions
Mirasol System for Whole Blood.
Biological
Lead sponsor
Terumo BCTbio
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 11, 2026, 5:24 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Reversal of Aspirin Antiplatelet Therapy With Cold Stored Platelets

NCT05111028
View directory record Official record
Conditions
Reversal of Platelet Aggregation Inhibitors
Interventions
Autologous Room Temperature stored Platelet transfusion, Autologous Cold Stored Platelet transfusion
Biological
Lead sponsor
Bloodworks
Other
Eligibility
18 Years to 59 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Shared-Decision Making for Hydroxyurea

NCT03442114
View directory record Official record
Conditions
Sickle Cell Anemia, Children, Only
Interventions
Hydroxyurea SDM Toolkit, Clinician Pocket Guide
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 5 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Not applicable Interventional

Delayed Cord Clamping in Preterm Neonates

NCT02478684
View directory record Official record
Conditions
Premature Birth of Newborn, Infant, Very Low Birth Weight, Delayed Separation of Umbilical Cord, Placental Transfusion
Interventions
30 Seconds of placental blood transfusion, 60 Seconds of placental blood transfusion
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
28 Weeks to 35 Weeks
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Preventing Acute Chest Syndrome by Transfusion Feasibility Study

NCT00951808
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Single blood transfusion, Standard care
Biological · Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

NCT01566695
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
Oral Azacitidine, Placebo, Best Supportiv Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
40
States / cities
Berkeley, California • Beverly Hills, California • Duarte, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 11, 2026, 5:24 AM EDT
Completed No phase listed Observational

Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell

NCT02561312
View directory record Official record
Conditions
Anemia, Sickle Cell, Sickling Disorder Due to Hemoglobin S
Interventions
Rapid manual partial exchange transfusion, Simple Transfusion
Other
Lead sponsor
Chattanooga-Hamilton County Hospital Authority
Other
Eligibility
3 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 11, 2026, 5:24 AM EDT
Recruiting Phase 2 Interventional

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

NCT05736419
View directory record Official record
Conditions
Sickle Cell Disease, Thalassemia, Beta, Thalassemia
Interventions
Fludarabine, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil, Rabbit ATG, Dexamethasone, Bortezomib, Rituximab
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 11, 2026, 5:24 AM EDT
Completed Not applicable Interventional Results available

Oral vs. Intravenous TXA Study Proposal: TJA

NCT02233101
View directory record Official record
Conditions
Blood Loss After Primary Total Joint Arthroplasty, Need for Blood Transfusion After Total Joint Arthroplasty
Interventions
Oral Tranexamic Acid, Intravenous Tranexamic Acid
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 11, 2026, 5:24 AM EDT
Terminated Phase 3 Interventional

INR-Triggered Transfusion In GI Bleeders From ER

NCT01461889
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Gastrointestinal Hemorrhage, Liver Diseases, Transfusion Related Lung Injury
Interventions
Transfuse plasma to High INR target, Transfuse plasma to Low INR target
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 11, 2026, 5:24 AM EDT